Posted on February 6, 2014 by Andrew Eaton
Scientists at the Danish pharmaceutical company H. Lundbeck A/S have published two papers, in the January 2014 issue of the journal “Drug Discovery Today”.
The first paper describes the context of toxicology in drug discovery, and their aim, which is to provide timely go/no go decisions (fail early) and direction to the discovery teams, by steering them away from safety risk but, importantly, also providing direction on what will not fail.
In the second paper, the team describes their compound testing strategies with respect to cardiovascular safety, hepatotoxicity, immunotoxicity, exploratory in vivo toxicity and genotoxicity and discloses the assays they have put in place to enable their strategy.
Lundbeck’s approach for genotoxicity includes the use of GreenScreen HC “to maximize the detection of potential carcinogens.” One reason cited for this is GreenScreen HC’s ability “to detect carcinogens that are not clastogenic or aneugenic, and are therefore not detected in the micronucleus assay.”
Links to the publishers website are given below:
- J.J.. Hornberg, et al., Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how, Drug Discov Today (2014), http://dx.doi.org/10.1016/j.drudis.2013.12.008
- J.J. et al., Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies, Drug Discov Today (2014), http://dx.doi.org/10.1016/j.drudis.2013.12.009